1 Min Read
* Verastem announces regulatory strategy for duvelisib, new drug application following guidance from FDA
* Verastem Inc - plans to submit NDA for duvelisib during Q1 of 2018 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.